secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039356
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated
--------------------------------------------------------------------------------

- Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).
- Cash $1.1B unchanged from year-end 2022; runway extends at least into 2025.
- BEACON trial: consented patients sufficient to fill sentinel and initiate expansion; initial data expected 2024.
- BEAM-201: first patient consented, dosing expected Q3 2023; multiple clinical sites open.
- BEAM-302 accelerated to first in vivo liver regulatory filing in Q1 2024; BEAM-301 filing in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/0000950170-23-039356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017023039356/beam-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer